Advanced Spine & Pain Management INC

Advanced Spine & Pain Management INC was paid $3.62M by Medicaid between Jan 2018 and Jun 2022, across 46 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 29% of everything it billed.

33Billing provider infoADVANCED SPINE & PAIN MANAGEMENT INC
CINCINNATI, OH 45230

33aNPI1790881746assigned 09/16/2006

33bProvider typeDurable Medical Equipment & Medical Supplies

28Total paid$3.62M

24GClaims117,888

24DCodes billed46

24AFirst – last monthJan 2018 – Jun 2022

Compared with peers

Next to other Durable Medical Equipment & Medical Supplies providers in Ohio

Rank by total paid#47 of 420

Median peer was paid$62K

This provider vs. median58×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	30,969	$971K
2019	34,392	$875K
2020	27,975	$721K
2021	18,068	$775K
2022	6,484	$273K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	29%	23,637	21,077	$1.04M
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	27%	33,643	29,735	$961K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	15%	14,657	13,306	$552K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	9.4%	4,450	3,923	$341K
62323		2.0%	601	514	$71K
80354		1.8%	6,376	6,060	$64K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	1.7%	957	881	$60K
80369		1.6%	5,498	5,225	$56K
80362		1.5%	2,977	2,849	$55K
80361		1.5%	2,980	2,831	$53K
80373		1.0%	3,657	3,504	$38K
93923		<1%	422	200	$36K

34 more codes

80356		<1%	3,266	$32K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	700	$31K
80355		<1%	2,977	$31K
80365		<1%	2,980	$29K
64493		<1%	438	$29K
99244	Office or other outpatient consultation, moderate to high complexity	<1%	299	$24K
64635		<1%	132	$15K
64494		<1%	447	$14K
95924		<1%	205	$13K
80346		<1%	591	$13K
J1030	Injection, methylprednisolone acetate, 40 mg	<1%	2,193	$10K
95923		<1%	201	$8K
80372		<1%	760	$8K
J1040	Injection, methylprednisolone acetate, 80 mg	<1%	740	$6K
64636		<1%	132	$6K
99215	Doctor's office visit, returning patient (complex)	<1%	75	$5K
E0730	Transcutaneous electrical nerve stimulation (tens) device, four or more leads, for multiple nerve stimulation	<1%	56	$3K
G0506	Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service)	<1%	585	$2K
A4595	Electrical stimulator supplies, 2 lead, per month, (e.g., tens, nmes)	<1%	72	$1K
64490		<1%	16	$1K
80348		<1%	72	$773.97
99490	Ccm add 20min	<1%	480	$763.62
64491		<1%	16	$535.09
99452		<1%	285	$507.49
99441		<1%	59	$380.68
80324		<1%	30	$331.02
G2012	Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion	<1%	60	$327.24
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	20	$243.53
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	66	$199.50
80360		<1%	16	$139.52
80335		<1%	16	$139.52
80359		<1%	16	$139.52
80367		<1%	16	$139.52
80368		<1%	16	$139.52

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKHAN, MUKARRAM (PRESIDENT)